- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02298010
Lymph Node Metastasis in Extended Lymphadenectomy for Gastric Cancer From a CLASSIC Trial
May 12, 2019 updated by: Seoul National University Hospital
Pattern and Clinical Implication of Lymph Node Metastasis From Gastric Cancer Which Was Resected by Radical Surgery With Extended Lymphadenectomy
The pattern of lymph node metastasis of the gastric cancer to each geographic lymph nose stations and the relation between each metastasis and survival are to be analyzed by retrospective review of medical records of who enrolled in the CLASSIC trial (NCT00411229) which have compared adjuvant chemotherapy and no adjuvant therapy after radical gastrectomy with extended lymphadenectomy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
899
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Study subjects who were enrolled in CLASSIC trial (NCT00411229) and whose medical records about the extent of the lymph node dissection and pathologic report are available.
Description
Criteria of previous CLASSIC trial:
Inclusion Criteria:
To be eligible for inclusion, each patient must fulfill each of the following criteria:
- Ambulatory males or females, aged ≥18 years.
- Karnofsky performance status of ≥70 %.
- Histologically confirmed gastric adenocarcinoma, staged pathologically, AJCC/UICC stage II (T2N1, T1N2, T3N0), IIIa (T3N1, T2N2, T4N0), and IIIb (T3N2). At least 15 examined lymph nodes are required to ensure the adequate TNM classification)
- Patients who underwent curative D2 lymphadenectomy resection for gastric cancer with no macroscopic or microscopic evidence for remaining tumor, who can be randomized to either study arm within 6 weeks after surgery.
- Give written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.
Exclusion Criteria:
Patients who fulfill any of the following criteria will be excluded:
- Serious concomitant medical illnesses that would limit life expectancy to < 5 years.
- Pregnant or lactating women.
- Women of childbearing potential with either a positive or no pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-child bearing potential.
- Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study.
- Any evidence of metastatic disease (including presence of tumor cells in the ascites).
- Previous cytotoxic chemotherapy, radiotherapy or immunotherapy except corticosteroids, for the currently treated gastric cancer.
- History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix.
- History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the Investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake.
- Clinically significant (i.e. active) cardiac disease e.g. symptomatic coronary artery disease, New York Heart Association (NYHA) grade II or greater congestive heart failure or serious cardiac arrhythmia requiring medication or myocardial infarction within the last 12 months.
- Lack of physical integrity of the upper gastrointestinal tract or those who have malabsorption syndrome likely to influence absorption of capecitabine, or inability to take oral medication.
- Known peripheral neuropathy ≥ CTCAEv3 grade 1. Absence of deep tendon reflexes (DTRs) as the sole neurologic abnormality does not render the patient ineligible.
- Organ allografts requiring immunosuppressive therapy.
- Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease.-
- Moderate or severe renal impairment [creatinine clearance equal to or below 50 ml/min (calculated according to Cockroft and Gault)], or serum creatinine > 1.5 x upper limit of normal (ULN).
- Any of the following laboratory values:
- Absolute neutrophil count (ANC) < 1.5 x 10^9/L
- Platelet count < 100 x 10^9/L
- Total bilirubin > 1.5 x ULN
- ALAT, ASAT > 2.5 x ULN
- Alkaline phosphatase > 2.5 x ULN.
- Prior unanticipated severe reaction to fluoropyrimidine therapy (with or without documented DPD deficiency) or patients with Kknown dihydropyrimidine dehydrogenase (DPD) deficiency.
- Hypersensitivity to platinum compounds or any of the components of the study medications.
- Received any investigational drug or agent/procedure, i.e. participation in another trial, within 4 weeks before randomization.
- Blood transfusions or growth factors to aid hematologic recovery within 2 weeks prior to study treatment start.
- Requirement for concurrent use of the antiviral agent sorivudine (antiviral) or chemically related analogues, such as brivudine.
- Unwilling or unable to comply with the protocol for the duration of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Adjuvant chemotherapy group
Research subjects who were enrolled in CLASSIC trial and underwent adjuvant chemotherapy.
|
|
Only surgery group
Research subjects who were enrolled in CLASSIC trial and did not undergo adjuvant chemotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Topographic pattern of metastasis to regional lymph node stations
Time Frame: at the time of surgery
|
at the time of surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
survival according to the metastatic lymph node station
Time Frame: 3 and 5years
|
3 and 5years
|
survival according to lymph node ratio
Time Frame: 3 and 5years
|
3 and 5years
|
recurrence pattern
Time Frame: 3 and 5years
|
3 and 5years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2016
Primary Completion (Actual)
February 1, 2016
Study Completion (Actual)
December 1, 2017
Study Registration Dates
First Submitted
November 19, 2014
First Submitted That Met QC Criteria
November 19, 2014
First Posted (Estimate)
November 21, 2014
Study Record Updates
Last Update Posted (Actual)
May 14, 2019
Last Update Submitted That Met QC Criteria
May 12, 2019
Last Verified
November 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Neoplastic Processes
- Neoplasm Metastasis
- Stomach Neoplasms
- Lymphatic Metastasis
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Capecitabine
- Oxaliplatin
Other Study ID Numbers
- ML29471
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stomach Neoplasms
-
Jeeyun LeeRecruitingStomach Cancer, AdenocarcinomaKorea, Republic of
-
Chinese University of Hong KongUnknown
-
Chinese University of Hong KongUnknown
-
National Cancer Center, KoreaUnknownSubmucosal Tumor of StomachKorea, Republic of
-
Chinese University of Hong KongRecruiting
-
Universitätsklinikum Hamburg-EppendorfOvesco Endoscopy AGSuspendedSubmucosal Tumor of StomachGermany
-
Xijing Hospital of Digestive DiseasesCompletedStomach Cancer | Esophageal Cancer | Esophageal Dysplasia | Stomach DysplasiaChina
-
Soonchunhyang University HospitalCompletedMalignant Neoplasm of Stomach | Benign Neoplasm of StomachKorea, Republic of
-
Fujian Cancer HospitalCompletedMalignant Neoplasm of Stomach Stage IVChina
-
Federation Francophone de Cancerologie DigestiveEli Lilly and CompanyActive, not recruitingStomach Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Stomach NeoplasmFrance
Clinical Trials on Capecitabine, oxaliplatin
-
Samsung Medical CenterNational Cancer Center, Korea; Asan Medical Center; Chonnam National University... and other collaboratorsCompletedColorectal CancerKorea, Republic of
-
Hebei Medical UniversityCompletedGastroesophageal Junction AdenocarcinomaChina
-
Samsung Medical CenterCompleted
-
Hebei Medical UniversityUnknownGastric Cancer | Liver MetastasisChina
-
AIO-Studien-gGmbHiOMEDICO AGTerminated
-
Peking UniversityTaiho Pharmaceutical Co., Ltd.Unknown
-
Hebei Medical UniversityUnknownGastroesophageal Junction AdenocarcinomaChina
-
Hebei Medical UniversityUnknownLiver Metastasis | HER-2 Positive Gastric CancerChina
-
University of Southern CaliforniaBristol-Myers Squibb; Sanofi; Roche Global DevelopmentUnknownGastric Cancer | Esophageal CancerUnited States
-
Royal Marsden NHS Foundation TrustCompletedColorectal CancerUnited Kingdom